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ABSTRACT
Obesity is a major public health challenge with a rapidly growing prevalence world-
wide. The condition increases the risk of multiple diseases, including cancer in dif-
ferent locations. Current evidence on the effect of intentional weight loss on cancer 
is inconclusive. Bariatric surgery results in extensive and sustained weight loss with 
positive impact on several obesity-related comorbidities. It can therefore serve as a 
proxy for intentional weight. The few studies available suggest that bariatric surgery 
may decrease overall cancer risk but increase the risk of cancer in specific tumor loca-
tions. This thesis assesses the impact of bariatric surgery on cancer risk and cancer 
mortality using the Nordic Obesity Surgery Cohort (NordOSCo). The cohort includes 
individuals with an obesity diagnosis recorded in the National Patient Registries in 
any of the five Nordic countries between 1980 and 2012. Study I and IV included 
Swedish cohort members only, while Study II and III included the entire cohort. 
Study I validated bariatric surgery codes in the Swedish Patient Registry and the 
Scandinavian Obesity Surgery Registry (SOReg) against medical records for bariatric 
surgery performed during 2011. The accuracy of the codes proved to be high; 93.5% 
in the Patient Registry and 98.6% in SOReg. However, one fifth of the procedures in 
SOReg were not registered in the Patient Registry, indicating that the completeness of 
bariatric surgery registrations in the Patient Registry can be improved. 
Study II evaluated the association between bariatric surgery and the risk of obesity-
related cancer, non-obesity related cancer and cancer in selected sites. The study found 
an overall decreased risk of cancer following bariatric surgery that was more evident for 
cancers associated with obesity, particularly breast cancer, endometrial cancer and non-
Hodgkin lymphoma in women. The lower cancer risk was primarily observed during 
the initial years following surgery and this decrease diminished with time after surgery. 
In contrast, the risk of kidney cancer was increased among bariatric surgery patients. 
Study III and IV focused on colorectal cancer and studied the impact of bariatric 
surgery on the risk and prognosis of this disease. Incidence rates of colon cancer were 
higher in bariatric surgery patients than in the general population, especially after ≥10 
years post-surgery. The elevated incidence rates exceeded that of obese individuals 
without bariatric surgery. No associations were observed for rectal cancer. On the con-
trary, cancer-specific mortality after rectal cancer diagnosis was more than three-fold 
increased among bariatric surgery patients compared to obese individuals without this 
surgery, but no differences in survival were observed between the exposure groups 
following colon cancer diagnosis. 
In conclusion, the Swedish Patient Registry is a valid data source for research on bari-
atric surgery. Overall cancer incidence seems to decrease after bariatric surgery, but the 
effect varies between cancer sites with a possible increase in the risk of colon and kid-
ney cancer. Bariatric surgery may also decrease the chance of survival in rectal cancer.
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Obesity and cancer are two major global public health challenges that are grow-
ing in scale with increasing economic prosperity and aging demographics.1,2 The 
health care needs associated with these conditions are putting substantial pressure 
on health systems that are already stretched to their limits. One of the important 
questions to address is therefore – how can society meet the future health care 
needs of its aging population with an increasing prevalence of obesity and cancer? 
A key public health intervention is prevention. There are clear links between 
obesity and multiple diseases requiring substantial health care resources, includ-
ing type 2 diabetes mellitus (T2DM), cardiovascular diseases and cancer.3 In 
fact, obesity is associated with cancer in no less than thirteen sites, and the list 
keeps  growing.4 Bariatric surgery has emerged as the only long-term effective 
treatment for morbid obesity, resulting in sustained weight-loss, improvement 
of comorbidities and prolonged life expectancy. However, this surgery may also 
lead to unintended outcomes such as increased risk of alcohol and drug depend-
ency,5,6 and possibly colorectal cancer.7,8 Far from all eligible patients are given 
the opportunity to undergo bariatric surgery, and opponents to publicly financed 
bariatric surgery argue that the health benefits do not necessarily offset the costs 
associated with surgery. Evaluation of the long-term benefits and consequences 
of this procedure would therefore provide policy makers with useful information 
when prioritizing health care resources. 
Since bariatric surgery did not become widespread until relatively recently, there 
are few epidemiological studies with follow-up exceeding ten years. This limita-
tion impedes on the interpretation of findings related to outcomes that take time 
to develop, such as cancer. Indeed, the paucity of research on intentional weight 
loss and cancer has been highlighted by the International Agency for Research 
on Cancer (IARC).4 
This thesis, consisting of four original studies, builds on a cohort of obese individu-
als from five Nordic countries with up to three decades of follow-up. The aim is 
to assess the long-term impact of bariatric surgery on cancer incidence and cancer 
prognosis that can inform clinicians and policy makers.
22 BACKGROUND
The Global Burden of Disease consortium estimated that the global prevalence of 
obesity in 2015 was 12% in adults and 5% in children, which is equivalent to 604 
million adults and 108 million children with obesity.1 Obesity is associated with 
several comorbidities, including cardiovascular diseases, cancer, T2DM, chronic 
kidney failure, musculoskeletal disorders, gastroesophageal reflux disease, liver 
steatosis, gallbladder disease, and sleep apnea.9 Taken together, it is estimated 
that 4 million deaths and 120 million disability-adjusted life years (DALYs) were 
attributed to excess body weight in 2015; cancer contributed to almost 10% of 
these excess deaths and DALYs.1 
2.1 Defintion of obesity
There are several measurements of body weight or body composition, including 
waist-to-hip ratio, waist-to height ratio, waist circumference, percent body fat, and 
body surface area. Body mass index (BMI) is the most widely used measurement 
and is calculated by dividing weight in kilograms by the square of height in meters 
(kg/m2). The World Health Organization (WHO) defines overweight as BMI ≥ 25 
kg/m2 and obesity as BMI ≥ 30 kg/m2 in adults. Obesity is subdivided into three 
classes and the highest class (morbid obesity) is equivalent to BMI ≥ 40 kg/m2.10 
However, there are a few caveats associated with BMI. The measurement does 
not provide details on body fat distribution or composition, and is often under-
estimated in elderly and overestimated in muscular individuals. In fact, abdominal 
obesity might be more strongly associated with cardiovascular disease, T2DM, 
and cancer than BMI.11 Furthermore, the BMI threshold for overweight and obe-
sity may not be appropriate for all ethnicities, as studies have observed that the 
association between BMI and percent body fat differs between ethnic groups.12 
However, owing to its simplicity and accessibility, BMI will likely remain one of 
the most widely used and studied measurements for body weight or composition. 
2.2 Obesity and cancer 
2.2.1 Obesity and cancer risk
According to IARC, obesity is associated with cancer in thirteen sites: esophagus 
(adenocarcinoma), gastric cardia, colon, rectum, liver, gallbladder, pancreas, breast 
(postmenopausal), corpus uteri, ovary, kidney (renal-cell), meningioma, thyroid, 
and multiple myeloma (Figure 1). The increase in relative risk (RR) is highest for 
endometrial cancer (RR 7.1; 95% CI 6.3-8.1) and esophageal adenocarcinoma (RR 
4.8; 95% CI 3.0-7.7). Limited evidence of an association was observed for fatal 
3prostate cancer, diffuse large B-cell lymphoma and male breast cancer.4 An umbrella 
review of systematic reviews and meta-analyses confirmed the association for the 
above mentioned sites, with the exception of thyroid cancer and meningioma.13 
Positive dose-response relationships between obesity and cancer incidence in sev-
eral studies support causality. A meta-analysis found that every 5 kg/m2 increase 
in BMI was strongly associated with the increased risk of several cancers, notably 
colon and thyroid cancer in men, endometrial and gallbladder cancer in women, 
and esophageal adenocarcinoma and kidney cancer in both sexes.14 Weight-gain 
during adulthood increases the risk of postmenopausal breast, endometrial, and 
ovarian cancer in women, colon cancer in men, and kidney cancer in both sexes.15 
Longer duration of obesity, as well as obesity in childhood, adolescence, and early 
adulthood, has also been linked to higher risk of obesity-related cancers.4,16 
In addition to evidence from epidemiological studies, experimental studies in 
animal models have found that obesity promotes tumorigenesis and cancer in the 
mammary gland, colon, liver, pancreas, prostate, skin, and leukemia.4 
Modified illustration from Centers for Disease Control and Prevention, Atlanta, GA, USA 
Figure 1. Thirteen cancer sites associated with obesity.
42.2.2 Obesity and cancer prognosis
Obesity is associated with increased cancer mortality, specifically in cancer of the 
esophagus, pancreas, colon, rectum, kidney, gallbladder, liver, multiple myeloma, 
and non-Hodgkin lymphoma in both sexes; prostate and gastric cancer in men; and 
breast, endometrium, cervix, and ovary cancer in women.17-19 Some of this excess 
mortality results from higher cancer incidence, but several studies have also shown 
an association between disease-specific survival after cancer diagnoses and BMI 
around the time of diagnosis, notably for breast cancer, while some evidence is 
also available for endometrial, ovarian, colorectal, and prostate cancer as well as 
hematologic malignancies.20-27 Studies on pancreatic cancer have shown conflicting 
results;28,29 no association was observed for esophageal cancer;30 and higher BMI 
was paradoxically associated with increased survival in kidney cancer.31 Weight 
gain after cancer diagnosis has also been associated with higher cancer-specific 
and all-cause mortality.32 Nevertheless, compared to studies on cancer risk the 
literature is sparse and less consistent.4 
Multiple factors may contribute to the inverse association between BMI and  cancer 
survival. Epidemiological studies suggest that obesity might be associated with 
larger tumor size and more aggressive tumor characteristics. For example, over-
weight and obese patients with breast and prostate cancer have an increased risk 
of tumor recurrence.33,34 Delayed diagnosis might be another contributing factor 
as obese patients often present with more advanced tumor stage at diagnosis.34,35 
Furthermore, cancer patients with obesity face challenges related to clinical manage-
ment and treatment of their cancer, such as insufficient dosing of chemotherapy, 
reduced efficacy of radiotherapy, and inferior outcomes after hormonal therapy.36
2.2.3 Mechanisms of action between obesity and cancer
Several pathways involving the endocrine, metabolic, inflammatory, and immune 
systems have been proposed to mediate the association between excess BMI and 
cancer (Figure 2). 
Insulin resistance and increased insulin secretion is common in individuals with 
obesity. Chronic elevated levels of insulin result in heightened activity of the insulin-
like growth factor 1 (IGF-1), which stimulates cell proliferation and migration, 
inhibits apoptosis, and enhances angiogenesis that are all linked to carcinogenesis. 
Elevated serum levels of IGF-1 have been observed for several malignancies.37
Insulin and IGF-1 also inhibit the synthesis of sex hormone-binding globulin 
(SHBG), the major carrier protein for testosterone and estradiol in plasma, and 
leads to elevated levels of bioactive sex steroids. Adipose tissue is also the main 
producer of estrogen in men and postmenopausal women, and contributes to 
elevated estrogen levels in obese individuals. Sex steroids regulate cell differen-
tiation, proliferation and apoptosis.38 In a pooled analysis of nine studies, women 
with higher concentration of sex steroids and decreased levels of SHBG had an 
5increased risk of post-menopausal breast  cancer.39 Similarly, elevated levels of estro-
gen and androgen have been associated with an increased risk of endometrial cancer.40 
Adipose tissue also synthesizes polypeptide hormones, such as leptin and adiponec-
tin. Leptin is known for suppressing appetite, but also promotes cell proliferation, 
inhibits apoptosis, and stimulates angiogenesis.37 Some studies have found an associa-
tion between leptin levels and the risk of prostate, colorectal, and breast cancer.41-43 
Adiponectin has anti-inflammatory properties and the opposite effect to leptin on 
cell growth, but its secretion is suppressed by insulin and estrogen. Epidemiological 
studies have found an inverse association between plasma concentrations of adi-
ponectin and cancer of the endometrium,44 breast,45 prostate,46 and possibly colon 
and rectum.47 
Additionally, obesity is associated with low-grade chronic inflammation, abnormal 
release of cytokines and acute-phase reactants, and activation of pro-inflammatory 
signalling pathways that might stimulate carcinogenesis.38 Finally, studies have pro-
posed that mechanical and oxidative stress might also contribute to the obesity-
cancer relationship.48 
Illustration from Tao W et al. Nat Rev Clin Onc, 2013;10:519-33
Figure 2. Proposed mechanisms of action linking obesity to cancer.36
62.2.4 Weight loss and cancer
Although plenty of literature supports an association between obesity and cancer, 
the impact of weight loss on cancer etiology and cancer outcomes is ambiguous. 
Preclinical studies have observed that calorie restriction inhibits tumor growth.49 
There are also some epidemiological evidence supporting an association between 
intentional weight loss and decreased cancer risk. One study reported that inten-
tional weight loss of ≥ 20 pounds in women reduced the risk of any cancer, and 
cancer in the breast, colon, and endometrium.50 Overweight and obese women who 
lost enough weight to reach the normal range of BMI had a cancer risk equivalent 
to normal-weight women.50 Intentional weight loss of ≥ 5% might also be associ-
ated with a decreased risk of breast and endometrial cancer,51-53 but this potential 
association could not be confirmed by all studies.54 A randomized clinical trial 
(RCT) of women free of cancer at baseline concluded that dietary interventions 
could decrease the risk of breast cancer and increase breast cancer survival.55 In 
contrast, no such benefit was observed for colorectal cancer or obesity-related 
cancer overall, but weight loss from the intervention in this study was modest and 
averaged 2.2 kg during the first year.56,57
In general, published literature on this topic is sparse and inconclusive. Some stud-
ies rely on self-reported weight loss that is vulnerable to biases. Another challenge 
is the difficulty of distinguishing between intentional and unintentional weight 
loss. The latter is associated with increased morbidity and mortality, and might 
mask any association between weight loss and cancer outcomes. Additionally, it 
is difficult to separate the effect of weight loss from that of physical activity, diet, 
and other lifestyle changes. Finally, although weight loss can be achieved through 
diet restriction, behavioral modifications, physical activity, and medical therapy, 
few of these conventional treatments have resulted in clinically meaningful weight 
loss in the long term, especially among individuals with morbid obesity.58 Bariatric 
surgery typically leads to substantial and long-lasting weight reduction and has 
served as a proxy for intentional weight loss in research. 
2.3 Bariatric surgery
2.3.1 Weight loss and health benefits of bariatric surgery
Health benefits derived from bariatric surgery have been demonstrated in several 
observational studies and a few RCTs. Bariatric surgery patients typically report 
a weight reduction of 25–30% within the first three years of surgery, compared to 
4–7% with medical therapy or lifestyle interventions.59-62 Sustained weight loss 
has been reported up to ten years after surgery.3 
The impact of bariatric surgery on morbidity, quality of life (QoL), and mortality 
is relatively well-documented, especially for T2DM. A meta-analysis of sixteen 
7studies reported that 64% of patients with T2DM experienced remission after 
 surgery, compared to 16% in patients on medical therapy.63 More recent RCTs have 
reported a T2DM remission rate of 30–70% up to five years after surgery.59-62,64 
Bariatric surgery can also improve hypertension, dyslipidemia, metabolic syndrome, 
obstructive sleep apnea, and musculoskeletal disorders, and have a protective 
effect on cardiovascular events, end-stage renal disease, and possibly cancer.3,65-67 
According to a meta-analysis, bariatric surgery significantly improves QoL, although 
the impact varied considerably across studies.68 In the RCTs that assessed QoL as 
one of the outcomes, a few or all of the eight QoL domains of the SF36 survey 
were improved up to five years after bariatric surgery.61,64 
Finally, bariatric surgery seems to have an overall long-term survival benefit, 
although studies with more than ten years of follow-up are limited. Compared to 
conventional treatment or no treatment, bariatric surgery reduced overall mortality 
with 41% according to a meta-analysis of eight observational studies.69 The risk 
reduction was greatest for T2DM (62–92%), followed by coronary heart disease 
(43–56%) and cancer (16–60%).70,71 However, overall mortality rates in bariatric 
surgery patients remained nearly twice as high as in the corresponding general 
population, and the survival benefit of the surgery seemed to decrease with time.71 
2.3.2 Bariatric surgery and cancer
2.3.2.1 Bariatric surgery and cancer risk
Cohort studies and meta-analyses have indicated that bariatric surgery might 
decrease overall cancer risk by 30–50%, with greater impact on obesity-related 
cancers than non-obesity related cancers.72-79 Assessments of specific cancer sites 
have generated mixed results, with strongest evidence observed for endometrial 
and breast cancer. Pooled results from observational studies on endometrial  cancer 
and breast cancer estimated risk reductions of 60% and 44%, respectively, after 
 bariatric surgery.80,81 In contrast, analyses of selected tumor sites in two meta-
analyses found either no statistically significant associations between bariatric 
surgery and any of the individual tumor sites78 or an association with breast  cancer 
only.79 
More recently, two matched cohort studies reported decreased risk of breast, 
endometrial, pancreatic, and prostate cancers.7,72 However, the two studies seem 
to present contradictory results for colorectal cancer. One study observed a 40% 
decreased risk of colon cancer and no statistically significant association with the 
risk of rectal cancer,72 while the other study found a more than two-fold increased 
risk of colorectal cancer.7 The association in the latter study was only significant for 
gastric bypass, and no analyses were undertaken for colon and rectum separately.7 
Other studies on colorectal cancer seem to indicate an increased risk after bariatric 
surgery as well, but results from the few available studies are highly inconsistent.8 
82.3.2.2 Bariatric surgery and cancer mortality
Cancer mortality rates seem to decrease after bariatric surgery, but there is  limited 
research on this topic. One cohort study found a 46% reduction in cancer mortality 
after bariatric surgery, with no difference between obesity-related and non-obesity 
related cancers.76 The authors of this study proposed that the lower cancer mortality 
rates in bariatric surgery patients were due to decreased cancer incidence, rather 
than increased cancer survival.76 A Nordic study confirmed the findings from the 
previous study, but observed a significant difference only during the initial five 
years after bariatric surgery.71 In fact, cancer mortality rates among bariatric  surgery 
patients in this study were lower than the rates in the corresponding general popu-
lation, indicating a potential selection bias where only individuals found to be free 
from cancer were probably considered for bariatric surgery.71 To our knowledge, 
there are no studies evaluating cancer survival after cancer diagnosis in bariatric 
surgery patients. 
2.3.2.3 Mechanisms of action between bariatric surgery and cancer
Based on the findings of a single study, bariatric surgery does not seem to have 
any independent effect on reduction of cancer risk, but the potential association is 
mediated through weight loss.82 Multiple mechanisms by which bariatric surgery 
may reduce cancer risk have been proposed. For example, post-operative remission 
of T2DM might counteract the insulin- and IGF-1 mediated carcinogenic effects 
of obesity.83 The level of SHBG might be restored as a result of improved insu-
lin sensitivity that lowers circulating levels of bioactive sex steroids.84 Bariatric 
surgery might also reduce plasma concentrations of estradiol and leptin, increase 
levels of adiponectin, decrease oxidative stress, and reduce chronic inflammation.85
2.3.3 Prevalence and indication of bariatric surgery 
Due to its health benefits and the relative safety of the procedure, bariatric surgery 
has increased rapidly in popularity worldwide. In the United States, the number of 
procedures increased from 158,000 to 216,000 between 2011 and 2016.86 According 
to a survey undertaken by the International Federation for the Surgery of Obesity 
and Metabolic Disorders (IFSO), 579,517 bariatric procedures were performed 
in 56 countries in 2014.87 Although reporting was incomplete, the survey results 
provide an indication of the scale and the geographical distribution of countries 
where these procedures are performed. 
The most common indication for bariatric surgery is BMI ≥ 40 kg/m2 in the absence 
of obesity-related comorbidity, or BMI ≥ 35 kg/m2 in the presence of at least one 
comorbidity. In reality, patients undergoing bariatric surgery often have BMI far 
above these thresholds.88 Some guidelines specify an upper age limit of 60 years 
9as the risk of postoperative morbidity and mortality increases with age.89 However, 
more recent studies suggest that bariatric surgery is a safe procedure in patients 
aged ≥ 65 and they should not be excluded solely due to age.90 Bariatric surgery in 
patients < 18 years is more controversial and evidence on long-term outcomes in 
this patient group is just beginning to emerge. The European Society for Pediatric 
Gastroenterology, Hepatology, and Nutrition recommends that bariatric surgery 
can be considered in “carefully selected” pediatric patients with BMI > 40 kg/m2 
and severe comorbidities, or BMI > 50 kg/m2 and mild comorbidities.91 
There are no absolute contraindications to bariatric surgery, but relative contrain-
dications include severe heart failure, unstable coronary artery disease, end-stage 
lung disease, active cancer treatment, portal hypertension, drug/alcohol depend-
ency, and severe mental illness unresponsive to treatment.92
2.3.4 Mechanisms of action of bariatric surgery
Bariatric surgery procedures can be roughly divided into three categories based on 
their mechanisms of action: malabsorptive procedures that interfere with digestion 
and absorption; restrictive procedures that limit intake; and mixed malabsorptive 
and restrictive procedures that act through both mechanisms.93 
Bariatric surgery leads to weight loss through multiple mechanisms, including 1) 
macronutrient and micronutrient malabsorption; 2) reduction in food intake and 
changes in food preferences; 3) altered secretion of gut hormones; 4) changes in gut 
microbiome; and 5) increased production of bile acids leading to improved metabo-
lism. The type of bariatric procedure affects which mechanisms come into play. 
In fact, it has been suggested that malabsorption induced by changes to the gastro-
intestinal anatomy accounts for <10% of reduction in total caloric intake after bari-
atric surgery.94 More importantly, bariatric surgery patients seem to adopt dietary 
modifications with preference given to vegetables and fruits over high-caloric 
beverages and foods.95 Changes in taste perception and food aversion, as well as 
early satiety and reduced hunger, also contribute to reduced daily caloric intake.94 
Furthermore, bariatric surgery might alter the secretion of gut hormones with 
increased regulation of appetite and elevated insulin levels as a result. Dietary and 
anatomical modification can also result in major changes in the gut microbiome that 
might have beneficial effect on insulin sensitivity and adiposity. Finally, bariatric 
surgery increases plasma levels of bile acids that are associated with improved 
glucose and lipid metabolism.94 
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2.3.5 Bariatric surgery procedures
Historically, six main procedures of bariatric surgery can be identified and grouped 
according to their mechanisms of action:96
• Malabsorptive: Jejunoileal bypass; 
• Mixed malabsorptive and restrictive: Roux-en-Y gastric bypass (gastric 
bypass) and biliopancreatic diversion with duodenal switch;
• Restrictive: Vertical banded gastroplasty, adjustable gastric banding (gastric 
banding), and sleeve gastrectomy.
According to the IFSO Global Registry, the most prevalent bariatric procedures 
between 2014 and 2018 was gastric bypass (53.2%) followed by sleeve gastrec-
tomy (45.9%) and gastric banding (5.0%).97 Figure 3 illustrates the most common 
procedures included in the studies of this thesis. 
2.3.5.1 Jejunoileal bypass
Jejunoileal bypass was one of the first bariatric procedures and developed in the 
1950s. This procedure circumvents most of the small bowel and leads to substantial 
and long-lasting weight loss. However, patients who underwent jejunoileal bypass 
were often afflicted with extensive complications such as electrolyte imbalance, 
vitamin and mineral deficiencies, severe diarrhea, gas bloat syndrome, kidney 
stones, and progressive liver degeneration. Consequently, most of these patients 
had their procedure reversed over time, and the procedure was eventually aban-
doned in favor of other safer procedures.96 
2.3.5.2 Gastric bypass
The first gastric bypass was performed in 1967 and quickly rose in popularity 
as it proved to be as effective as jejunoileal bypass in achieving weight loss, but 
had fewer long-term complications.93 Further modification of the procedure took 
place in the following years, and it is now the most widely performed bariatric 
 procedure globally.97 In this procedure most of the stomach, duodenum, and proxi-
mal jejunum are bypassed, and a jejunojejunostomy restores continuity with the 
biliopancreatic limb (Figure 3). 
2.3.5.3 Biliopancreatic diversion with duodenal switch
The biliopancreatic diversion was first performed in the late 1970s and devel-
oped to avoid some of the complications associated with jejunoileal bypass. The 
procedure consists of a partial horizontal gastrectomy draining into a food limb 
through a gastrojejunostomy that joins the biliopancreatic limb to form the com-
mon segment. The biliopancreatic diversion with duodenal switch replaces the 
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horizontal hemi-gastrectomy with a pylorus-saving vertical sleeve gastrectomy 
combined with a duodenoileostomy and a longer common segment (Figure 3). This 
procedure is reported to have fewer sides effects than biliopancreatic diversion.93 
The biliopancreatic diversion with or without duodenal switch are technically 
difficult and time-consuming operations, but can offer better outcomes than the 
other bariatric procedures in terms of weight loss and remission of comorbidities.98 
2.3.5.4 Vertical banded gastroplasty
The vertical banded gastroplasty was developed as an alternative to procedures 
with an enteric or gastric bypass, and widely performed in the 1980s and 1990s. 
In this procedure, a vertical stomach pouch is stapled and the outlet is restricted 
with a mesh or silicon band (Figure 3). However, complications such as stenosis 
of the outlet, rupture of staple line, and weight regain due to gastric pouch enlarge-
ment often required surgical revision. Eventually, this procedure was abandoned 
in favor of the laparoscopic gastric banding.96 
2.3.5.5 Adjustable gastric banding
The adjustable gastric banding quickly became the procedure of choice in the 
1990s and early 2000s. The procedure involves the placement of an adjustable 
band horizontally around the upper stomach to create a small pouch (Figure 3). 
The band was made adjustable by means of a silastic cuff that could be filled or 
drained with fluid from a subcutaneous valve. However, failure to achieve long-
term weight loss and complications, such as band slippage and perforation, has 
led to a rapid decline in popularity. 
2.3.5.6 Sleeve gastrectomy
Due to the high complication and mortality rates associated with biliopancreatic 
diversion with duodenal switch, the sleeve gastrectomy was proposed as a first-
stage operation in a two-stage procedure. The sleeve gastrectomy consists of a 
longitudinal gastrectomy that leaves a tunnel-shaped gastric remnant with an intact 
pylorus. In many patients, weight-loss after this first-stage operation was sufficient 
and the second stage operation was no longer necessary.93 Sleeve gastrectomy 
became a stand-alone procedure in the mid-2000s and is now the fastest growing 
bariatric procedure globally. However, long-term outcomes and complications 
are yet to be evaluated.96 
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Illustration by Ketevan Kandelaki
Figure 3. Four bariatric surgical procedures: gastric banding, biliopancreatic diversion 
with duodenal switch, vertical banded gastroplasty, and adjustable gastric banding.
2.3.5.7 Complications and short-term mortality 
Complication and perioperative mortality rates after bariatric surgery have decreased 
substantially since its first introduction, and are now comparable with several 
commonly performed surgical procedures such as cholecystectomy and coro-
nary bypass surgery.99 According to a meta-analysis, perioperative mortality was 
higher for mixed surgical procedures than for restrictive, and for open surgery than 
laparoscopic surgery.69 
Complication rates vary substantially between studies and surgical procedures. 
The most serious early complication after bariatric surgery is anastomotic leak 
that has a mortality rate of 15%. Other early complications include anastomotic 
stenosis; bleeding at the staple line; and thromboembolic events.100 Late compli-
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cations from gastric banding include band slippage that may lead to obstruction 
and ischemia of the stomach wall in serious cases; band erosion; and dilation of 
the esophagus. Late complications after gastric bypass include marginal ulcers 
resulting in bleeding or perforation; internal hernia with small bowel volvulus; 
and gallstone disease.100 
Side effects from bariatric surgery include dumping syndrome that appears after 
ingestion of high-calorie foods and leads to abdominal pain, nausea, tachycardia 
and light headedness; and micronutrient deficiency, primarily of iron, calcium, 
vitamin B12, and vitamin B9. 
Reported risk factors for severe complications, including mortality, are older 
age, male sex, smoking, T2DM, congestive heart failure, hypertension, previous 
abdominal surgery, and hypoalbuminemia. 101,102 
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3 AIMS
The overall aim of the thesis was to contribute to the body of knowledge on long-
term outcomes after bariatric surgery, specifically focusing on cancer risk and 
prognosis.
To achieve this objective, a cohort was compiled as a central piece of this  thesis 
consisting of individuals with obesity diagnoses in the five Nordic countries 
(Denmark, Finland, Iceland, Norway, and Sweden). As bariatric surgery identi-
fied from the national patient registries was the exposure of interest, one of the 
objectives was to validate the bariatric surgery codes in these registries to ensure 
correct assignment of exposure status. 
The four study-specific aims addressed in this thesis are: 
• To assess the accuracy and completeness of bariatric surgery registrations in 
national health registries (Study I);
• To clarify the association between bariatric surgery and the risk of obesity-
related and non-obesity related cancer (Study II);
• To specifically address the association between bariatric surgery and 
colorectal cancer risk (Study III);
• To assess the association between bariatric surgery and colorectal cancer 
prognosis (Study IV).
Since the hypothesis differs between colorectal cancer and other cancers in rela-
tion to bariatric surgery, these outcomes were addressed in two separate studies 
(studies II and III). In study II, we hypothesized that weight-loss through bari-
atric surgery reduces overall cancer incidence rates, particularly of obesity-related 
cancers. Based on previous findings, study III hypothesized that bariatric surgery 
increases the risk of colorectal cancer due to anatomical and physiological changes 
in the gastrointestinal tract induced by surgery.
15
4 MATERIALS AND METHODS
4.1 Overview
Table 1. Overview of the study design and statistical analyses in study I-IV.
STUDY I STUDY II STUDY III STUDY IV
Study design Validation study Cohort study
Setting Sweden Denmark, Finland, Iceland, 
Norway, Sweden
Sweden
Study period January 1 – 
December 31, 2011
January 1, 1980 – 
December 31, 2015
January 1, 1980 – 
December 31, 2012








·	 Cause of Death Registries




 bariatric surgery in 
the two registries 
within the study period
Obesity diagnosis in the 
Patient Registries
Obesity  diagnoses in 
the Patient Registry 
and colorectal  cancer 
diagnoses in the 
Cancer Registry
Exposure Not applicable Bariatric surgery
Main 
outcome(s)








specific mortality and 
all-cause mortality
Confounders Not applicable Sex, calendar period, 
length of follow-up, country, 
diabetes (only study II)








·	 Cox proportional 
hazards model





This thesis builds primarily on data derived from nationwide registries in the 
Nordic countries. For study I, data from a quality registry and medical records 
were also obtained. 
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4.2.1 National health and population registries
The Nordic countries are widely known for their long history of nationwide 
population-based registries that were originally established for administrative 
purposes, but have since become important data sources for social and health-
related research. There are a number of national registries containing a wealth of 
individual-level information about a country’s residents. The most well-known 
for health-related research include the patient registry, cancer registry, cause of 
death registry, prescribed drug registry, medical birth registry, and the registry of 
the total population. Linkages between the registries are made possible by means 
of a unique individual identifier (personal identity code) assigned to all residents, 
making these data sources a “gold mine” for epidemiological research.103 The 
studies in this thesis use data from the sources described below. 
4.2.1.1  Patient registries
The national patient registries record all episodes of hospital care in the country 
and include information on patient characteristics and health care providers; dates 
of admission, operation and discharge; and codes for surgical procedures and 
discharge diagnoses. 
Although the Nordic patient registries were established over a time period of three 
decades, the evolution of these registries has largely been the same and usually 
starts with somatic inpatient care to then gradually expand to psychiatric care, 
outpatient specialized care, and day surgery. Sweden was first to establish the 
patient registry in 1964, but nationwide coverage was not achieved until 1987. 
The patient registries in the other Nordic countries had complete national cover-
age nearly from inception (Table 2). 
Discharge diagnoses are coded according to the International Statistical Classification 
of Diseases and Related Health Problems (ICD) in all countries, but there may be 
country-specific modifications to the ICD codes. Introduction of new ICD versions 
occurred largely simultaneously across countries, with the exception of Denmark 
that migrated directly from ICD version 8 (ICD-8) to version 10 (ICD-10).104 
Surgical procedures are coded based on the Nordic Medico-Statistical Committee 
(NOMESCO) Classification of Surgical Procedures from the mid-1990s and 
onwards, and includes specific codes for bariatric surgery.105 Country-specific 
coding systems of surgical procedures were used prior to NOMESCO, but did not 
include specific codes for bariatric surgery with the exception of Sweden. 
The patient registries from primarily Denmark, Finland and Sweden have been 
validated through several studies, showing overall high accuracy but with sub-
stantial variation between diagnoses. Reviews of validation studies found positive 
predictive values (PPVs) ranging from 15%-100% in the Danish registry, 75%-
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99% in the Finnish registry, and 85%-95% in the Swedish registry depending on 
diagnosis; trauma or injury and cardiac events turned out to be the most accurately 
recorded diagnoses.106-108 
4.2.1.2 Cancer registries
The national cancer registries in all Nordic countries are nationwide, with a long 
history of mandatory reporting of cancer cases dating back to the 1950s and 
60s.109 Denmark is the sole exception, where reporting became mandatory only in 
1987 (Table 2).109 The cancer registries include information on date of diagnosis, 
 topography, morphology, behavior or malignancy, patient demographics, and source 
of confirmation. Some registries also include tumor stage and treatment.110 There 
is a high degree of completeness and comparability between the Nordic cancer 
registries, but some differences in registration practices exists, as detailed below. 
Information on new cancers are collected from multiple sources, including hospitals 
and long-term care, primary care physicians, pathology and cytology laboratories, 
and death certificates. There are some differences in data sources between cancer 
registries in the Nordic countries, most notably for Sweden that is the only country 
where information from death certificates are not included.110 It is estimated that this 
missing data source accounts for approximately 4% of all cancer cases111 and the 
underreporting affects primarily cancers frequently diagnosed in advanced stages, 
such as pancreas, biliary tract, lung, esophagus, and liver  cancer.110 A Swedish vali-
dation study of pancreatic and biliary tract cancers found substantial underreporting 
of these cancers to the cancer registry when compared to the patient registry and 
cause of death registry. The study suggested that this discrepancy was due to the 
common use of imaging as the basis for diagnosis, rather than histopathological 
confirmation, at these tumor sites.112 
There are also some differences in coding practices between countries that may 
affect cross-country comparisons of cancer incidence rates and interpretation of 
trends over time. These include differing rules for inclusion of premalignant and 
borderline malignant tumors that primarily affect tumors of the urinary bladder, 
brain, and central nervous systems; and different counting practices of multiple 
tumors in the same organ, which is especially relevant for paired organs (for 
 example lung, breast, and kidney). Furthermore, variations in screening programs 
may affect comparability of cervical, breast, and colorectal cancer incidence 
between countries.110 
4.2.1.3 NORDCAN
To provide comparable cancer data across the Nordic countries and address con-
cerns related to differing coding practices over time, the NORDCAN database 
was initiated in 2002 by the Association of Nordic Cancer Registers and the 
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IARC. NORDCAN consists of information from the national cancer registries 
and converts the data into a uniform international standard by first recoding the 
tumors into the International Classification of Diseases for Oncology version 3 
(ICD-O-3) and then into ICD-10. The tumors are then grouped into NORDCAN-
specific categories, i.e. NORDCAN entities. Thus far, 41 cancer sites or entities 
are included in the common database, and the national cancer registries include a 
separate variable for the NORDCAN entity code.113 Cancer incidence rates for the 
general population, grouped according to the NORDCAN entities, can be obtained 
from their online database.114 
4.2.1.4 Cause of death registries
The first cause of death registries were established in the mid-20th century (Table 2). 
Causes of death are derived primarily from death certificates and the registries 
include the date and place of death, underlying and contributing causes of death, 
autopsy, and patient demographics. The coverage of the registries is high; for 
example, the date of death and underlying cause of death in the Swedish registry 
was 100% and 96% complete, respectively.115 However, only a few studies have 
validated the cause of death. One Swedish study compared death certificates to 
medical records from the final hospitalization, and found 77% agreement between 
the cause of death on the certificate and the expected cause of death based on the 
medical records.116 The agreement was highest for malignant tumors where the 
death certificates were accurate in 90% of cases.116 According to a Danish study, 
30% of the causes of death were changed after autopsy.117 Since autopsy rates have 
dropped significantly since the 1970s and are now completed in only 10% of all 
deaths in Denmark and Sweden, this might have a negative impact on the quality 
of death statistics, but its effect seem to vary depending on the cause of death.115,117 
4.2.1.5 Total population registries 
The total population registries in the Nordic countries were established during the 
1950s to 70s and are some of the oldest population registries in Europe (Table 2). 
These registries contain vital statistics such as dates of birth and death, sex, 
country of birth, citizenship, immigration and emigration, family demographics, 
and individual and contextual socioeconomic variables.118,119 The quality of these 
registries is considered high, especially with regards to data reported by profes-
sional or administrative personnel. Self-reported data, such as that of residency and 
migration, is likely to be of lower quality. It is estimated that close to 100% of all 
births and deaths in Sweden are reported within 30 days, whereas 5% of immigra-
tions and 9% of emigrations are either reported after 30 days or never reported.119 
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Table 2. National health- and population registries and their year of initiation in five 
Nordic countries.




Denmark 1977/1978a 1942/1987b 1970 1968
Finland 1967 1952/1961b 1969 1971
Iceland 1999 1954 1952 1953
Norway 1997 1952/1953b 1951 1964
Sweden 1964/1987a 1958 1952 1968
aInitiation/Nationwide coverage
bInitiation/Mandatory reporting
4.2.2 Swedish quality registries
There are more than 100 national quality registries (NQR) in the Swedish health 
care system with the primary aim to monitor and improve the quality and outcome 
of care.120 The NQRs cover a wide range of diseases and areas in the healthcare 
sector, and have in recent years also become an important source for research. 
The registries usually include detailed individual-level information on diagnoses, 
treatments, outcomes, and patient characteristics. Unlike the national health regis-
tries, participation in NQR is voluntary both for health care providers and patients. 
They operate by the opt-out principle, meaning that patients are included in the 
NQRs unless they actively withdraw after being informed about the registries.121 
4.2.2.1 Scandinavian Obesity Surgery Registry
The Scandinavian Obesity Surgery Registry (SOReg) was initiated in 2004 and 
covers all bariatric surgery centers in Sweden since 2013. The inclusion rate of 
bariatric surgeries performed in Sweden is estimated to 99%.122 The SOReg con-
tains mandatory information on patient demographics and anthropometric meas-
urements, health care providers, comorbidities, complications, readmissions and 
reoperations at baseline and 6 weeks, 1 year, 2 years and 5 years post-operative. 
Optional information includes laboratory test results, blood pressure measurements, 
use of vitamins and mineral substitutions, and QoL measurements. Additional 
information on the bariatric surgery is entered after the operation. Completion rates 
were 100% for the mandatory variables and 67% for the optional ones in 2015.122 
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4.2.3 Medical records
In this thesis, medical records were considered as the “gold standard” against 
which bariatric surgery registrations in the SOReg and the patient registry were 
compared. Paper copies of electronic medical records from relevant episodes of 
care were requested from surgical departments in 44 hospitals around Sweden. 
The collected medical records included notes from admissions, operations, and 
discharges. 
4.3 Study design 
4.3.1 Validation of the bariatric surgery code
In study I, bariatric surgery procedures performed in Sweden from January 1 
to December 31, 2011 were identified from the SOReg and the Swedish patient 
 registry. A total of 8 501 bariatric surgery registrations were identified from the 
two registries and divided into five categories (A–E) through cross-tabulation 
using the personal identity code, hospital name and date of admission (Figure 4): 
A. Procedures that are either i) only identified in the SOReg, or ii) identified in 
both registries but with a non-bariatric surgery code in the patient registry; 
B. Procedures that are identified in both registries and matches on admission date 
and surgical procedure; 
C. Procedures that are identified in both registries and matches on admission date, 
but not surgical procedure;
D. Procedures that are only identified in the patient registry and have a concurrent 
diagnosis code for obesity; 
E. Procedures that are only identified in the patient registry, but without a concur-
rent diagnosis code for obesity.
4.3.1.1 Sampling strategy
For validation purposes, all registrations from category C, D, E, and non-gastric 
bypass procedures from category B were selected for validation. Random  samples 
were drawn from procedures in category A and gastric bypass procedures in 
 category B. Sample size was determined based on the assumption of ≥ 95% 
 coherence between medical records and the registries, with a precision of ± 0.03 
or less. The sampling procedure was undertaken with assistance from the National 















Figure 4. Distribution of bariatric surgery procedures performed in 2011 according to 
the validation categories (A–E) in the Swedish patient registry and the Scandinavian 
Obesity Surgery Registry (SOReg). Presented as total number of bariatric surgery 
 procedures/number of validated procedures.
4.3.1.2 Data collection
To enable retrieval of medical records for comparison with the registries, personal 
identity number, hospital name, and date of admission for the selected episodes 
of care were provided by the Swedish National Board of Health and Welfare. 
Information from the medical records was manually extracted based on a predefined 
template. To evaluate potential auditor bias, double-entry by two reviewers were 
undertaken for 10% of the medical records and assessed for interrater reliability, 
which was found to be high (PPV = 92%, kappa value = 0.81). 
4.3.2 Nordic Obesity Surgery Cohort
Studies II-IV in this thesis are based on the Nordic Obesity Surgery Cohort 
(NordOSCo). 
The NordOSCo is a population-based retrospective cohort based on registry data 
from Denmark, Finland, Iceland, Norway and Sweden spanning from 1964 to 
2015. There are some differences in study periods between countries due to data 
availability, i.e. 1976 to 2015 for Denmark, 1968 to 2012 for Finland, 1999 to 
2012 for Iceland, 2007 to 2011 for Norway, and 1964 to 2012 for Sweden. While 
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the health and population registries in Norway contain data from several decades 
back in time, linkages between the registries using a unique personal identifier 
was not possible prior to 2007. 
The cohort includes all individuals who received a diagnosis of obesity in the 
Nordic patient registries during the study period. For these individuals, all avail-
able data from the patient registries were extracted for the study period. To  collect 
additional information, linkages were made to the cancer registries, cause of death 
registries and total population registries. Figure 5 illustrates the specific variables 
available in the NordOSCo. When several registries contained the same demo-
graphic variable (e.g. sex, date of birth, and date of death), we combined this 
information from the registries in a step-wise hierarchical fashion to obtain the 
most complete demographic data.123 
PATIENT REGISTRY  
CANCER REGISTRY  
POPULATION REGISTRY  
- Admission date  
- Discharge date  
- Discharge diagnoses  
- Procedure codes 
CAUSE OF DEATH REGISTRY  
- Birth date  
- Death date  
- First emigration date   
- Sex 
- Sociodemographic data  
- Death date  
- Causes of death   
- Diagnosis date  
- Topography 
- Morphology 
- NORDCAN entity code  
- Behavior code (benign/malign)   
- Tumor number  
- Basis for diagnosis   
Figure 5. National health and population registries from which data for the Nordic 
Obesity Surgery Cohort (NordOSCo) were retrieved and the variables included.123 
4.3.2.1  Inclusion criteria
Figure 6 illustrates the overall data management process and selection of partici-
pants into the NordOSCo. 
Studies II and III include all individuals in NordOSCo with a diagnosis of obe-
sity aged 18 or above at study entry. Individuals who received a diagnosis of any 
cancer (study II) or any colorectal cancer (study III) prior to the date of obesity 
diagnoses were excluded. Study IV includes all Swedish individuals in NordOSCo 
with an obesity diagnosis and a colon or rectal cancer diagnosis in the Swedish 













































































































































































































































































































































































































date of their first obesity diagnosis or date of bariatric surgery were excluded, as 
well as individuals whose first emigration occurred prior to the colorectal cancer 
diagnosis. 
4.3.2.2 Exposure
The exposure of interest in studies II-IV was bariatric surgery. Exposed indivi-
duals were identified from operation codes in the patient registries. In Denmark, 
Finland, Norway, and Iceland, no specific codes for bariatric surgery were avail-
able prior to the NOMESCO Classification of Surgical Procedures. Sweden used 
a country-specific classification system from 1980 to 1996 that contained bariatric 
surgery codes. 
As illustrated in Figure 7, the number of bariatric surgeries performed in the Nordic 





























Denmark Finland Iceland Norway Sweden
Figure 7. Number of bariatric surgeries per 100,000 inhabitants in five Nordic  countries 
between 1980 and 2012 based on data from the Nordic Obesity Surgery Cohort 
(NordOSCo).123
The predominant type of bariatric procedure has also changed over time. Restrictive 
procedures such as gastric banding and vertical banded gastroplasty dominated 
in the 1980s and 1990s, and were mostly performed in Sweden during this time 
period. Since the 2000s, gastric bypass is the treatment of choice in most cases 
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and outweighs all other bariatric procedures combined (Figure 8).123 Outside the 
NordOSCo study period, sleeve gastrectomy has become increasingly popular but 
the procedure does not have a specific surgical code in NOMESCO. It is, therefore, 
not possible to separate sleeve gastrectomy from the other bariatric procedures 
























































































Gastric banding Gastric bypass Vercal banded gastroplasty Malabsorpve
Figure 8. Number of bariatric surgeries by type of procedure performed between 1980 
and 2012 in five Nordic countries based on data from the Nordic Obesity Surgery 
Cohort (NordOSCo).123
4.3.2.3 Outcomes
The main outcomes of study II were the incidence of any cancer, any obesity-related 
cancer and any non-obesity related cancer. The definition of obesity-related cancer 
was based on the viewpoint of the IARC working group and included malignancies 
from thirteen sites.4 The cancer events were identified from the national cancer 
registries and tumor topography was determined based on NORDCAN entity codes. 
Secondary outcomes included specific tumor sites with a minimum of 20 cancer 
events in the bariatric surgery group. Study III focused on the incidence of colon 
and rectal cancer that were identified from the national cancer registries using 
ICD-O-3 codes. The main outcome of Study IV was colorectal cancer-specific 
mortality and the secondary outcome was all-cause mortality. The dates and causes 
of death were ascertained from the Swedish cause of death registry. Colorectal 
cancer-specific deaths were identified from ICD codes, and both underlying and 
contributing causes of death were considered.
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4.3.2.4 Study period
Due to limitations in exposure data, as described above, the study periods spanned 
from 1996-2015 in Denmark, 1997-2012 in Finland, 1999-2012 in Iceland, 2007-
2011 in Norway, and 1980-2012 in Sweden. As a result, the population size of 
studies II-IV is smaller than the NordOSCo population, as individuals exited the 
cohort before the start of study period. 
4.4 Statistical analyses
4.4.1 Validation of the bariatric surgery code
To measure the agreement between operative procedures described in the medical 
records and bariatric procedures recorded in the registries in study I, PPV with 
95% confidence interval (CI) was estimated. 
PPV is most commonly used in the context of diagnostic tests and is defined as the 
probability that a subject with a positive test truly has the disease. In this case, PPV is 
the probability that a surgical procedure with a bariatric surgery code in the registry 
truly is a bariatric surgical procedure according to the medical records (“positive”).
Three PPVs were calculated: 
1) Overall concordance, i.e. any bariatric procedure is considered “positive” 
regardless if the type of procedure is correctly recorded or not; 
2) Concordance accounting for the type of bariatric procedure, i.e. the bariatric 
procedure is considered “positive” only if the specific type of procedure is 
correctly recorded; 
3) Concordance accounting for the type of bariatric procedure and weighted 
accordingly. 
Since non-gastric bypass surgeries were oversampled in the study and misclas-
sification was considered to be more likely for these procedures, a weighted PPV 
was calculated to adjust for potential underestimation. The assigned weight corre-
sponded to the proportion of the type of procedure among all bariatric procedures 
in the sample. Thus, more common procedures would have a greater impact on the 
overall PPV. The statistical analyses were performed using the statistical software 
SAS 9.4 (SAS Institute). 
4.4.2 Nordic Obesity Surgery Cohort
The main statistical methods in studies II-IV were survival analysis and indirect 
standardization. All statistical tests were two-sided and results were considered 
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statistically significant at a 5% significance level. The statistical software STATA 
14 (StataCorp LP, College Station, Texas, USA) was used for all statistical analyses. 
4.4.2.1 Follow-up
In studies II and III, unexposed person-time was accumulated from the date of 
obesity diagnosis (or the inception date of the country-specific study period should 
it occur after the date of the first obesity diagnosis) until any of the following 
events, whichever occurred first: 
• Diagnosis date for the outcome(s) of interest
• Date of the first bariatric surgery
• Date of death
• Date of first emigration
• End of study period 
Exposed person-time was counted from the date of the first bariatric surgery 
until the outcome(s) of interest, death, emigration, or end of study period. Thus, 
 exposure was treated as a time-varying covariate in the analyses, and an individual 
who had undergone bariatric surgery could contribute with both unexposed and 
exposed person-time. 
In study IV, time to event was defined as time elapsed from the date of the first 
colon or rectal cancer diagnoses until the date of death, emigration, or end of study 
period. Exposure status did not change with time in this study, as individuals with 
a colorectal cancer diagnoses prior to bariatric surgery were excluded. 
4.4.2.2 Survival analysis
To evaluate the association between bariatric surgery and the outcomes of interest 
in studies II-IV, the outcome among exposed and unexposed were compared using 
multivariable Cox proportional hazard models to calculate hazard ratio (HR) with 
95% CI. Covariates considered for the final models were based on subject-matter 
knowledge and formal assessment with the likelihood ratio test and the Akaike 
information criterion using a backward stepwise approach. 
The final model in study II included the covariates sex, diabetes, calendar period, 
length of follow-up, and country. Proxy indicators for tobacco smoking (chronic 
obstructive pulmonary disease) and excess alcohol consumption (alcohol depend-
ency, and alcohol-induced liver disease, neuropathy, cardiomyopathy, gastritis, and 
pancreatitis) were also considered but did not significantly improve model fit. In 
study III, the final model adjusted for sex, calendar period, length of follow-up, 
and country. Based on evidence from literature, T2DM, inflammatory bowel dis-
ease, tobacco smoking and excess alcohol consumption were also considered as 
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confounders but were excluded from the final model after formal assessment of 
model fit. To assess changes in association over time in both studies, separate HRs 
by follow-up periods were estimated through the introduction of an inter action 
term between the exposure variable and length of follow-up. 
Study IV adjusted for sex, age at colorectal cancer diagnosis, education level, 
and calendar period. To assess differences in HRs between tumor sites (colon and 
rectum), an interaction term was introduced between the exposure variable and 
tumor site. To account for missing data on education level in 4% of the patients, 
multiple imputation under the missing at random assumption was undertaken. 
4.4.2.3 Indirect standardization
To compare cancer incidence rates among individuals in the NordOSCo to cancer 
incidence rates in the general population, standardized incidence ratios (SIRs) with 
95% CIs were calculated separately by exposure group in studies II and III. SIR 
is estimated by dividing the observed number of cancer events to the expected 
number of events, which is derived from sex-, age- and calendar year-specific 
cancer incidence rates in the corresponding background population of the Nordic 
countries. These rates were obtained from the NORDCAN database in study II 
and the national cancer registries in study III. Stratified analyses by follow-up 
periods were also conducted. 
4.5 Ethical considerations
Ethical approvals and data retrieval permissions for all studies were sought and 
granted by the relevant authorities in each country. Registry-based research does 
not require ethical approval in Denmark and Finland, and is exempt from informed 
consent in all Nordic countries. 
Registry data for studies II-IV were delivered stripped of all personal identifiable 
information. The electronic datasets were stored on university servers or the server 
of Statistics Denmark, and only accessible to a few individuals involved with 
data management and analyses for the research project. For study I, the Swedish 
National Board of Health and Welfare conducted the linkage between registries, 
and personal identity codes were only shared for the individuals whose bariatric 
surgery procedures were selected for validation. All electronic datasets containing 
personal identifiable information were password protected and only accessible to 
a few researchers involved with the study. Paper copies of medical records and 
datasets on compact discs were stored in safes on locked university premises. For 
data entry and analyses, personal identity codes were substituted with unidentifiable 
replacement code. The key between the replacement codes and the personal identity 
code was erased after completion of the study. Results from all studies in this thesis 
are presented at the aggregated level.
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5 RESULTS
5.1 Validation of the bariatric surgery code
In study I, 938 (98%) medical records from 44 clinics were received out of the 
962 records requested for validation purposes. Most of the missing medical records 
belonged to bariatric surgery registrations without a concurrent obesity diagnosis 
code in the Swedish patient registry (n=19). 
The estimated PPVs are presented in Table 3 for the patient registry and the SOReg. 
There was high agreement between the medical records and the registries, especially 
for the SOReg. Concordance was higher for gastric bypass than non-gastric bypass 
procedures. The most common errors included misclassification of sleeve gastrec-
tomy as gastric bypass or vertical banded gastroplasty in the patient registry, and 
misclassification of rarer types of procedures (such as gastric plication and duodenal 
switch with prior sleeve gastrectomy) as gastric bypass in both registries. However, 
misclassification was most common for “non-bariatric” procedures that were incor-
rectly coded in 17 out of 35 cases in the patient registry, and 2 out of 9 cases in 
SOReg. “Non-bariatric” procedures included reconstructions to normal anatomy 
or removal of gastric band after previous bariatric surgery, endoscopic procedures, 
reoperation due to complications from bariatric surgery, interrupted bariatric surgery, 
and tumor surgery. Half of the registrations that lacked an obesity diagnosis in the 
patient registry were bariatric surgeries (n=32), whereas the rest were made up of 
“non-bariatric” surgical procedures (n=30). 
Almost one fifth (n=1,554) of the bariatric surgeries registered in SOReg were not 
included in the patient registry or were registered with a non-bariatric surgery code 
in the patient registry (n=56). These missing procedures included mainly gastric 
bypass (n=1,580), sleeve gastrectomy (n=17), reconstruction to normal anatomy 
after previous bariatric surgery (n=10), biliopancreatic diversion with duodenal 
switch (n=2) and other procedures (n=1). 
Table 3. Concordance of bariatric surgery registration between medical records and 
the Swedish patient registry or Scandinavian Obesity Surgery Registry (SOReg), 
presented as positive predictive values (PPVs) with 95% CI.
Surgical procedure PPV (95% CI)
Swedish Patient Registry SOReg
Bariatric surgery, overall 97.0 (95.6-98.4) 99.7 (99.3-100.0)
Bariatric surgery, by type of procedure 93.5 (91.5-95.5) 98.6 (97.7-99.5)
Bariatric surgery, by type of procedure 
and weighted
96.5 (95.0-98.0) 99.7 (99.3-100.0)
Gastric bypass 96.8 (95.1-98.5) 99.8 (99.5-100.0)
Other bariatric surgery 88.6 (83.8-93.4) 97.4 (94.9-99.9)
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5.2 Nordic Obesity Surgery Cohort 
Table 4. Selected characteristics of individuals in study II-IV from the Nordic Obesity 
Surgery Cohort (NordOSCo). 
STUDY II STUDY III STUDY IV
Total population size 482,572 468,384 1,463
Median follow-up,  
years
Exposed 3.1 3.0 3.7
Unexposed 4.2 4.2 4.3
Sex
Female 326,689 317,217 744
Male 155,883 151,167 719
Median age at study entry, years 45 45 56
Country
Denmark 195,341 188,340 NA
Finland 83,801 73,741 NA
Iceland 14,850 13,977 NA
Norway 32,408 33,922 NA
Sweden 156,172 158,404 1,463
Bariatric surgery 49,096 48,035 131
Gastric bypass 35,541 36,191 34
Restrictive 10,791 4,108 90
Other 2,764 7,736 7
Main outcome Any cancer Colorectal 
cancer
Death
Exposed 1,314 147 45
Unexposed 24,565 2,912 596
NA=Not applicable
5.2.1 Bariatric surgery and cancer risk
5.2.1.1 Compared to the general population
In study II, overall cancer incidence rate among bariatric surgery patients was 
not increased (SIR 1.00; 95% CI 0.95-1.06) compared to the cancer incidence 
rate in the corresponding general population. There was a slightly increased risk 
of non-obesity related cancer (SIR 1.15; 95% CI 1.02-1.29) and a decreased risk 
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of obesity-related cancer (SIR 0.90; 95% CI 0.82-0.99) in this group (Figure 9). 
In contrast, cancer incidence rates in obese individuals without bariatric surgery 
were increased by 22% (SIR 1.22; 95% CI 1.19-1.24) compared to the general 
population, and the risk increase remained significant for both obesity-related and 
non-obesity related cancers (Figure 9). 
The increased risk of non-obesity related cancer among bariatric surgery patients 
was only statistically significant during the first five years after surgery (SIR 1.36, 
95% CI 1.12-1.66). The decreased risk of obesity-related cancer was observed up 
to a decade post-surgery (SIR 0.80, 95% CI 0.67-0.95 for 0-4 years post-surgery; 
SIR 0.84, 95% CI 0.72-0.98 for 5-9 years post-surgery). 
5.2.1.2 Compared to obese individuals without bariatric surgery
Bariatric surgery patients had a lower overall risk of cancer (HR 0.89; 95% CI 
0.83-0.94) compared to obese individuals without this surgery (Figure 10). The 
lower risk was most evident during the first five years post-surgery (HR 0.77, 
95% CI 0.67-0.88 for obesity-related cancers; HR 0.86, 95% CI 0.76-0.99 for 
non-obesity related cancers). 
Sub-analyses by nine tumor sites indicated a decreased risk of breast cancer 
(HR 0.81; 95% CI 0.69-0.95), endometrial cancer (HR 0.69; 95% CI 0.56-0.84) 
and non-Hodgkin lymphoma (HR 0.64; 95% CI 0.42-0.97) in women, and an 
increased risk of kidney cancer (HR 1.44; 95% CI 1.13-1.84) in both sexes after 
bariatric surgery (Figure 10). 
Figure 9. Cancer incidence rates in obese individuals with and without prior  bariatric 
surgery compared to cancer incidence rates in the general population. Presented as 
standardized incidence ratio with 95% confidence interval.
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Figure 10. Cancer risk in men and women comparing bariatric surgery patients to obese indi-
viduals without bariatric surgery for all cancer, obesity-related cancer, non-obesity related 
cancer and selected cancer sites. Presented as hazard ratio with 95% confidence interval.
5.2.2 Bariatric surgery and colorectal cancer risk
5.2.2.1 Compared to the general population
In study III, the incidence rate of colon cancer among bariatric surgery patients 
was higher than the corresponding rate in the general population (SIR 1.61; 95% 
CI 1.32-1.95). This elevated colon cancer risk exceeded that of obese individuals 
without bariatric surgery (SIR 1.34; 1.28-1.40). There was no increased risk of rectal 
cancer compared to the general population for either exposure group. 
Stratified analyses by follow-up periods indicated that the increased risk of colon 
cancer among bariatric surgery patients was highest ≥ 10 years after surgery (SIR 
2.19, 95% CI 1.41-3.22). In contrast, the risk increase of colon cancer in obese 
individuals without bariatric surgery remained stable around 30% over time. 
5.2.2.2 Compared to obese individuals without bariatric surgery
No statistically significant differences in colon or rectal cancer incidence were 
observed between bariatric surgery patients and the obese comparison group 
(Figure 11). Sub-analyses by follow-up periods indicated a possible increased 
risk of colon cancer with time after surgery, but the difference was only statisti-
cally significant for the follow-up period 10-14 years after surgery (HR 1.69, 95% 
CI 1.11-2.55). 
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5.2.3 Bariatric surgery and colorectal cancer survival
5.2.3.1 Compared to obese individuals without bariatric surgery
In study IV, bariatric surgery patients with a diagnosis of colorectal cancer were 
compared to obese colorectal cancer patients without previous bariatric surgery. 
The study identified 32 cases of colorectal cancer-specific deaths and 13 cases of 
deaths by other causes among patients with colorectal cancer and previous bari-
atric surgery. The corresponding numbers in the obese comparison group were 
354 deaths due to colorectal cancer and 242 deaths due to other causes. A Kaplan-
Meier survival plot for bariatric surgery patients and the obese comparison group 
with colorectal-cancer specific mortality as the outcome is illustrated in Figure 12.
Colorectal cancer-specific mortality (HR 1.50, 95% CI 1.00-2.19) and all-cause 
mortality (HR 1.62, 95% CI 1.18-2.22) was higher in bariatric surgery patients than 
the obese comparison group. These findings were primarily driven by a three-fold 
increase in mortality among rectal cancer patients with bariatric surgery, whereas 
no significant difference in mortality was observed between the exposure groups 
with colon cancer (Figure 11). 
Figure 11. Comparison of cancer incidence, cancer-specific mortality and all-cause 
mortality between bariatric surgery patients and the obese comparison group, presented 
as hazard ratio with 95% confidence interval. For mortality estimates, only individuals 
with a diagnosis of colon cancer or rectal cancer were included.
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Figure 12. Colorectal cancer-specific survival proportion of obese individuals with and 
without prior bariatric surgery in Sweden from 1980 to 2012. 
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6 METHODOLOGICAL CONSIDERATIONS
The robustness of the results in studies I-IV is affected by the study design and 
the degree to which systematic and random errors appear. 
6.1 Study design
Epidemiological studies are observational or experimental. It is generally accepted 
that well-designed experimental studies generate strongest evidence, as randomiza-
tion of treatment or exposure increases the likelihood that confounders (observed 
and unobserved) are equally distributed between exposure groups. It is thus 
assumed that the only difference between the groups is the exposure. However, 
random allocation is not always possible or ethically acceptable. In these cases, 
well-designed observational studies are appropriate. 
Studies II-IV in this thesis are observational and retrospective in nature, as expo-
sure and outcomes occurred before cohort enrollment and data collection. The 
longitudinal cohort design accounts for temporality and ensures that the expo-
sure occurred before the outcome. An alternative to the cohort study could be a 
quasi-experimental study design where treatment allocation is not random, such 
as the Swedish Obese Subjects (SOS) study.3 However, nationwide coverage in 
five countries would be virtually impossible to achieve with this latter option and 
require a long period of prospective data collection.
6.2 Validity 
Random and systematic errors affect the validity of the study, i.e. the extent to which 
inferences can be drawn for the source population from which the study sample 
is obtained (internal validity), and the degree to which results can be generalized 
to other settings (external validity).124 Random errors or variations that occur by 
chance are unpredictable and cannot be replicated by repeating the study. In con-
trast, systematic errors (or biases) are errors in the design or execution of a study 
that systematically distorts the association between the exposure and outcome.124 
Figure 13 illustrates the correlation between random and systematic errors.
There are inherent sources of errors affecting the validity of all epidemiological 
studies. To what extent the study results can be inferred to the source population 
and the target population depends on the impact of these errors on the direction 
and magnitude of the results. The validity of the results is therefore based on the 











Figure 13. Random error versus systematic error and the effect on validity. 
6.2.1 Bias
There are three common types of biases in epidemiological studies: selection bias, 
information bias, and confounding. 
6.2.1.1 Selection bias
Selection bias occurs when the composition of the study sample does not reflect 
the population for which the results are inferred. Thus, any associations found in 
the study may not be transferrable to the source population or the target population.
Selection bias in study I can be considered low, since either all or a random  sample 
of the bariatric surgery registrations in the different categories were included. Only 
2% of the requested medical records were not received, and while the missing 
records mostly belonged to cases lacking an obesity diagnosis, sensitivity analyses 
showed limited impact on PPV estimates. 
Studies II-IV are nationwide population-based cohort studies that include virtu-
ally all patients with a documented obesity diagnosis in any of the five Nordic 
 countries for up to three decades. The risk of selection bias and loss to follow-up 
can be considered low due to the choice of data sources and study design. Any loss 
to follow-up most likely to occured in individuals who failed to report their emi-
gration status to the authorities, and is unlikely to differ between exposure groups. 
Bariatric surgery in the Nordic countries are predominantly publicly financed and 
thus captured by the patient registry. Selection bias of exposed individuals should 
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therefore be limited. According to study I, the Swedish patient registry captured 
> 80% of the bariatric surgery registrations in SOReg in 2011. The missing pro-
cedures included mainly gastric bypass and a few sleeve gastrectomy. 
The representativeness of obese individuals in the comparison group in relation to 
the larger Nordic obese population is, however, unknown. No study has validated 
the obesity diagnoses in the patient registries, and the circumstances under which 
patients receive an obesity diagnosis during hospitalization is unclear. It is likely 
that only a fraction of the obese Nordic population is captured through the patient 
registries, and these individuals may be afflicted with poorer health status. For 
example, based on self-reported weight and height in the national public health 
questionnaires, the Swedish Public Health Agency estimated that the prevalence 
of obesity in the Swedish adult population was 14% in 2012.125 This is equivalent 
to 1.15 million adults, a considerably higher number than the Swedish population 
in NordOSCo. However, low response rates (49% in 2012) and response bias may 
affect the validity and reliability of the results from the national questionnaires.126
In general, identifying a suitable comparison group to study the long-term impact 
of bariatric surgery is a challenge common to most observational studies due to 
difficulties in obtaining anthropometric measurements from the general popula-
tion. A quasi-experimental design could address some of the concerns related to 
the recruitment of an appropriate comparison group. However, such an approach 
is likely to seriously limit the study sample size and length of follow-up, and be 
influenced by biases associated with recruitment of study participants. Another 
option is to use the medical birth registry that includes information on maternal 
weight and height upon enrollment in maternity care. However, this would restrict 
the source population to females who have given birth in the Nordic countries and 
may limit the study’s external validity. Furthermore, a BMI ≤ 30 in the medical 
birth registry does not necessarily indicate that the individual will not develop 
obesity at a later point. 
6.2.1.2 Information bias
Information bias (or measurement bias) arises from inaccurate measurement or 
classification of key data such as exposure, outcome, or confounders, and can be 
categorized as non-differential or differential. The exposure or outcome is equally 
misclassified between the comparison groups in non-differential misclassification, 
resulting in risk estimates biased towards the null. In differential misclassification, 
the misclassification of exposure or outcome is unequally distributed between 
the comparison groups, and the risk estimates can be biased in either direction.127
To address measurement bias of bariatric procedures in study I, interrater reliability 
was assessed and showed high agreement between the investigators, indicating a 
low risk of systemic misclassification related to the type of bariatric procedure. 
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Furthermore, study I concluded that the validity of bariatric surgery codes in the 
patient registry is high, which indicates a low risk of misclassification by expo-
sure in studies II-IV. 
Misclassification of outcomes in studies II-IV can also be considered low. The 
Nordic cancer registries have overall high completeness and validity. There is some 
underreporting of cancer cases in the Swedish cancer registry because death cer-
tificates are not considered. Since a large proportion of bariatric surgery patients 
are Swedish, the exposed group may be differentially affected by missed cases. 
However, the overall proportion of missed cancer events in the Swedish cancer 
registry is small (4%) and such potential differential misclassification should thus 
be negligible. Some misclassification may also occur in the categorization of tumor 
sites due to variations in coding practices between countries, and might affect 
study III. Any such misclassification of tumor sites should be non-differential 
between exposure groups. 
The completeness of the Nordic cause of death registries is also high, and valida-
tion studies of these registries indicate that the underlying cause of death is most 
accurate for malignant tumors.116 In study IV, both underlying and contributing 
causes of death were considered to ensure that colorectal cancer-specific deaths are 
captured. This might have overestimated the number of colorectal cancer-specific 
deaths by misclassifying some cases of deaths due to other causes, but any such 
misclassification should be non-differential between exposure groups. 
Covariates in the models of studies II-IV included sex, age at study entry,  calendar 
period, follow-up time, and country. The risk of misclassifying any of these covari-
ates should be low; sex and date of birth were cross-checked between registries, 
and calendar period and follow-up time were generated automatically from the 
data. Diabetes was included as a covariate in study II and identified from the 
patient registries. Because most cases of T2DM are treated in primary health care, 
the patient registries underestimate the prevalence of this disease. This misclas-
sification might be differential since T2DM is an indication for bariatric surgery 
and therefore less likely to be missed in the exposure group. The impact of this 
potential bias on the magnitude of the point estimates is, however, difficult to 
predict. In study IV, education level was included as a proxy for socioeconomic 
status and was derived from the Swedish total population registry that collects 
this information from different sources, including university and high school reg-
istrations, the Swedish public employment service, and the population census.128 
As a result, education level of immigrants might be less accurate, but should be 




A confounder refers to a third factor that spuriously affects the association between 
an exposure and an outcome. It is independently associated with the exposure and 
outcome without being a part of the causal pathway, in which case it is referred to 
as a mediator (Figure 14).127 The confounding effect can be limited or eliminated 
either in the study design stage or the analysis phase. Adjustment of mediators 
could partially or completely remove the effect of the exposure on the outcome, 













Figure 14. Directed acyclic graph of exposure and outcome in relation to confounders 
and mediators, exemplified through study II-IV.
Confounding factors were addressed at the analyses stage in studies II-IV by adjust-
ing for known factors that might confound the association between the exposure and 
outcome in multivariable Cox regression models. Selection of covariates to include 
in the models was based on subject-matter knowledge through literature review 
and observation of the data. For example, comparison of exposed and unexposed 
individuals in NordOSCo revealed that the unexposed group is  generally older at 
study entry, more likely to be male, have a higher prevalence of cardiovascular 
diseases and chronic obstructive pulmonary disease, and a slightly lower prevalence 
of diabetes and hypertension than the exposed group. Inclusion of covariates in 
the final model was then determined through model selection based on model fit. 
Some potential confounding factors could not be accounted for due to lack of data 
or insufficient data. These included BMI and behavioral risk factors such as physi-
cal activity, nutrition, tobacco smoking, and excess alcohol intake. Proxy indica-
tors were used to assess potential confounding by smoking and excess alcohol 
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use, but were excluded from the final models as they did not improve model fit. 
However, the lack of effect may have been caused by insufficient data on these two 
risk factors for cancer. Furthermore, a range of unknown factors may influence the 
association between exposure and outcome. In the absence of randomization, it is 
difficult to exclude confounding entirely in epidemiological studies. 
6.2.2 Precision
Random error (or random variability) is inversely related to statistical precision. A 
major contributor to random variation is the selection of study subjects, i.e. sam-
pling. It is assumed that any study population is sampled from a “super- population” 
that the study applies to. Thus, even population-based studies including entire 
populations (such as studies II-IV) are subject to sampling error. Another source 
of random error is the unexplained variation in measurements of exposure and 
outcome, such as the observed cancer incidence or mortality rates in this  thesis. 
Key data on exposures, outcomes, and confounders are therefore subject to both 
systematic and random measurement errors.127 One way of improving precision 
is by increasing sample size, and this approach was taken in studies II-IV. By 
including study subjects from entire populations in the Nordic countries, the 
study sample was maximized using available data sources. Another possibility is 
to improve statistical efficiency through study design, for example by matching 
study subjects on different characteristics.127 
In statistical analyses, precision is most commonly presented as CI or P values. 
CIs with a level of 95% can be interpreted as the following: if the study was to be 
repeated numerous times with different samples taken from the super-population 
at each time and 95% CIs computed for each of them, then 95% of these inter-
vals would contain the true value of the super-population.127 In simplified terms, 
CI can be considered as the range of values within which the true value of the 
super-population is likely to be. In related terms, the P value is the probability of 
observing a difference between comparison groups in the study sample, although 
no difference exists in the super-population (type I error). If multiple tests are run 
in a study with a significance level of P ≤0.05, the likelihood of observing statis-
tically significant differences even if no true difference exists is 5%. Strategies to 
reduce type I errors include lowering the significance level and multiple testing 
corrections. The consequence of both strategies is an increased risk of type II errors, 
i.e. failing to observe a statistically significant difference even if a true difference 
exists. None of these strategies were adopted in studies I-IV. Instead, the studies 
attempted to reduce the number of tests by addressing predefined hypotheses and 
only considering covariates that were selected based on subject-matter knowl-
edge. Type I error might explain some of the spurious findings in study II where 
an increased risk of kidney cancer among bariatric surgery patients was found, 
which has rarely been observed in previous studies. Similarly, study IV found 
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a strongly increased risk of rectal cancer mortality in bariatric surgery patients 
that was not seen for colon cancer. Type II errors are counteracted by the large 
 sample sizes in studies II-III. However, the power of the test (i.e. the probabil-
ity of  observing a difference in the study sample when there is a true difference) 
might have been insufficient for sub-analyses by single tumor sites and follow-up 
periods in  studies II-III. 
6.2.3 Generalizability 
External validity or generalizability refers to the extent to which results from the 
study population can be inferred to populations in other settings.127 While external 
validity does not affect internal validity, studies with poor internal validity should 
not be generalized. The studies in this thesis are population-based and build on 
nationwide registries of the entire population in one or more Nordic countries. This 
aspect in itself merits high external validity, unless there is a reason to believe that 
the mechanisms by which bariatric surgery acts on cancer risk and prognosis differ 
between the Nordic populations and populations from other settings. 
Most of the bariatric surgeries in NordOSCo were gastric bypasses and conducted 
after the 2000s. Type of bariatric procedure may affect the success rate of long-term 
weight-loss.129 Therefore, the study results might be more appropriately applied 
to this procedure and in modern contexts. 
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7 GENERAL DISCUSSION
7.1 Validation of the bariatric surgery code
The high level of accuracy in coding of bariatric surgeries in the Swedish patient 
registry and the SOReg in study I confirms that these registries are appropriate 
data sources for identifying study populations that have undergone bariatric sur-
gery. Given the similarities between the Nordic patient registries, it is reasonable to 
assume that the level of accuracy for bariatric surgery codes found in the Swedish 
patient registry is similarly high for the other countries. 
Bariatric surgery registrations without a concurrent obesity diagnosis in the patient 
registry are most prone to errors. Excluding these registrations might increase the 
specificity of bariatric surgery cases, and this strategy was therefore adopted for 
studies II-IV. 
One-fifth of the registered procedures in the SOReg were not found in the patient 
registry. This indicates, at least in Sweden, that the coverage of bariatric surgeries 
in the patient registry is incomplete. It is unclear if the same issue is encountered 
in the other countries. A possible explanation might be lower reporting rates to 
the patient registry of bariatric surgeries conducted in private practice. Further 
exploration of the reasons behind these missing cases could be useful to improve 
the completeness and quality of the patient registry. 
7.2 Nordic Obesity Surgery Cohort
Studies II-IV is based on the NordOSCo that is likely to be one of the largest 
bariatric surgery cohorts to date with some of the longest follow-up. Two previ-
ously published retrospective cohort studies on bariatric surgery from England 
and the United States included larger sample sizes, but the number of bariatric 
surgery patients was smaller than in the NordOSCo for both studies.130,131 With up 
to three decades of follow-up and low risk of loss to follow-up, the NordOSCo is 
well suited for studying long-term outcomes of bariatric surgery, such as cancer. 
Although the cohort includes individuals from five countries, the study population 
can be regarded as rather homogeneous due to similarities in sociodemographic 
characteristics and genetic profiles, as well as comparable lifestyles, cultures, and 
health care systems across the Nordic countries. 
7.2.1 Bariatric surgery and cancer risk
Results from study II indicate that the overall risk of cancer, particularly obesity-
related cancer, is decreased after bariatric surgery. The impact was greatest for 
endometrial cancer, breast cancer, and non-Hodgkin lymphoma in women. The 
decreased risk of cancer in the endometrium and breast is in line with previously 
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published literature.80,81 Two studies on bariatric surgery and cancer risk at single 
tumor sites found no statistically significant association with non-Hodgkin lym-
phoma, but the point estimates indicated a decreased risk in both cases that were 
of similar magnitudes as study II.74,76 
Paradoxically, the risk of kidney cancer was increased after bariatric surgery. The 
mechanisms behind this finding are unclear; one potential explanation is that bari-
atric surgery increases the risk of kidney stones that is associated with papillary 
renal carcinoma.132,133 In support of this finding, a study from England showed that 
bariatric surgery patients had a strongly increased risk of kidney cancer compared 
to the general population, which exceeded the elevated risk of kidney cancer among 
obese individuals without bariatric surgery.131 
Although not statistically significant, results from study II suggest that the inverse 
association between bariatric surgery and cancer was strongest during the first five 
years post-surgery, and that the effect seemed to gradually diminish with time after 
surgery. The lack of statistically significant associations during the later follow-
up periods could be due to smaller sample size. Another potential explanation is 
that bariatric surgery patients often slowly regain some of the initial weight-loss 
after surgery, possibly resulting in declining benefits from the surgery.129 Similar 
 patterns have been observed for other obesity-related comorbidities, such as T2DM 
and hypertension.134 The immediate effect of bariatric surgery on cancer incidence 
is surprising given the typically slow pathogenesis of tumor development and the 
expected time it may take to reverse the carcinogenic mechanisms. Two possible 
explanations could contribute to these findings. First, relative contraindications 
and pre-operative screening for comorbidities might select healthier individuals for 
bariatric surgery with an overall lower risk of cancer. Alternatively, the comparison 
group of obese individuals without bariatric surgery identified from the patient 
registry might have poorer health status and a generally higher risk of cancer than 
the overall obese population. Second, most bariatric surgery patients with less than 
five years of follow-up entered the cohort in the latter part of the study period 
when gastric bypass was the procedure of choice. Gastric bypass typically results 
in greater weight-loss than restrictive procedures, which might partially explain 
some of the greater reductions in cancer risk during the early follow-up periods. 
7.2.2 Bariatric surgery and colorectal cancer risk
Contrary to the study hypothesis, no statistically significant difference in  colorectal 
cancer rates was observed between bariatric surgery patients and the obese  comparison 
group in study III. However, in support of the hypothesis, colon cancer rates in the 
bariatric surgery population were elevated compared to the corresponding general 
population, and exceeded that of obese individuals without bariatric surgery. No 
such trend was observed for rectal cancer. 
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The impact of bariatric surgery on colorectal cancer risk has been evaluated in a 
few previous studies with conflicting results. Two North American studies found 
no impact of bariatric surgery on colorectal cancer risk,74,76 whereas a meta-analysis 
of four studies concluded that the risk was reduced.135 A previous study based on 
a subset of the Swedish population in NordOSCo found a two-fold increased risk 
of colorectal cancer in bariatric surgery patients ten years after surgery compared 
to obese individuals without bariatric surgery.8 These results were confirmed by 
a more recent study from England that found an elevated colorectal cancer risk of 
similar magnitude as the Swedish study, and the risk seemed to increase with time 
after bariatric surgery.7 To our knowledge, no prior study has assessed the impact 
of bariatric surgery on colon and rectal cancer risk separately. 
The mechanisms underlying a potential increase in colon cancer risk following 
bariatric surgery are unclear; hyperproliferation of the bowel mucosa, increased 
levels of biomarkers, and changes in the gut microbiome resulting from gastroin-
testinal reconstruction might contribute to the tumorigenesis.136-138 Furthermore, 
exposure of the distal bowel to increased levels of bile acids might cause mechanical 
stress to the mucosal cells that are normally not in contact with these fluids, and 
could provide some explanation to the observed differences between colon and 
rectal cancer risk in study III. In fact, a study examining the association between 
cholecystectomy (that results in changes to the bile flow) and intestinal cancer 
demonstrated a clear gradient effect in which the elevated risk of cancer reduced 
with increasing distance from the common bile duct.139 Detection bias might also 
contribute to the observed higher rate of colon cancer in bariatric surgery patients, 
as these patients are more likely to be in regular contact with health care during 
the years following surgery. It does, however, not explain the possible increasing 
trend of colon cancer incidence with time after surgery. 
7.2.3 Bariatric surgery and colorectal cancer survival
Interestingly, study IV found a three-fold increase in cancer-specific mortality 
and overall mortality among rectal cancer patients with previous bariatric surgery 
compared to obese individuals without this surgery. In contrast, no statistically 
significant increase in mortality was noted for bariatric surgery patients with colon 
cancer. These results are unexpected given that individuals who have undergone 
bariatric surgery seem to be at greater risk of colon cancer than rectal cancer, and 
there is also a stronger association between obesity and colon cancer than obesity 
and rectal cancer.140 Half of the study population lacked information on tumor 
stage, but among individuals for whom data was available a higher proportion of 
bariatric surgery patients had stage IV tumors. However, since tumor stage was 
considered a mediator in the causal pathway between bariatric surgery and cancer 
survival, we did not adjust for this variable. Other unknown and known potential 
confounders for which data were lacking (e.g. BMI) might contribute to these 
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spurious findings. Differences in etiology, morphology, tumor behavior, and treat-
ment between colon and rectal cancer might also play a role in the findings, but 
their potential impact is only speculative at this stage. Finally, we cannot exclude 
that the observed results for rectal cancer are due to random errors. 
7.3 Implications and future research
The beneficial effect of bariatric surgery on morbidity and mortality has been 
demonstrated in a number of studies. This thesis contributes with additional evi-
dence supporting a protective effect of bariatric surgery on the risk of cancer and 
provides further arguments in favor of this surgery. 
However, a potential increased risk of colon cancer and kidney cancer following 
bariatric surgery was also identified. Taking available literature into account, these 
observations might justify heightened awareness of colon cancer in this patient 
group. Bariatric surgery patients presenting with new onset bowel symptoms should 
probably undergo colonoscopy promptly to rule out colon cancer, and individuals 
with additional risk factors for colon cancer might be candidates for screening 
interventions. The results on kidney cancer are unexpected and warrant further 
research before any clinical implications can be inferred. If bariatric surgery indeed 
increases the risk of colon cancer and kidney cancer, identifying patients at higher 
risk of these cancers could help improve early detection of these tumors. So far, 
studies on cancer risk after bariatric surgery are mainly observational. The RCTs 
on bariatric surgery with T2DM as primary outcomes are yet to publish any results 
on cancer.59-62 These trials could provide a unique opportunity to study the effect 
of bariatric surgery on cancer in a controlled setting. 
There is a paucity of studies addressing the impact of bariatric surgery on cancer 
survival after diagnosis. To our knowledge, no previous studies have evaluated the 
association between bariatric surgery and disease-specific mortality among cancer 
patients. The unexpected finding of poorer survival in rectal cancer but not colon 
cancer among bariatric surgery patients in study III warrants further research to 
confirm a potential association and explore possible underlying mechanisms in 
order to identify risk groups and interventions. Such studies should also explore 
the impact of bariatric surgery on cancer survival in other tumor sites. 
Overall, identifying individuals who would benefit most from bariatric surgery in 
the short- and long-term could assist clinicians and policy makers in prioritizing 
limited health care resources. Large cohorts such as NordOSCo may help in iden-
tifying predictive factors for favorable or poor outcomes after bariatric surgery. 
Future research using NordOSCo would benefit from a better understanding of 
the comparison group, i.e. individuals with an obesity diagnoses but no bariatric 
surgery in the patient registry. This can be achieved through a validation study 
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of the obesity diagnosis code through in-depth review of medical records and 
patient charts that include anthropometric measurements for a randomly selected 
number of individuals in the cohort. Linkage of NordOSCo to additional health- 
and population registries would allow access to a range of informative variables. 
These registries could include the medical birth registry, prescribed drug registry, 
and quality registries for bariatric surgery in the Nordic countries, amongst others. 
With the rising prevalence of obesity globally, demand for bariatric surgery is 
expected to increase. In 2010, Denmark changed its eligibility criteria for publicly 
financed bariatric surgery from BMI ≥ 40 kg/m2 to ≥ 50 kg/m2.141 This policy change 
resulted in a drastic reduction in the number of publicly financed bariatric surger-
ies.88 The indication for bariatric surgery in Denmark changed again in 2017 and 
returned to the original BMI threshold. Policy changes, such as the one adopted 
in Denmark, offer additional opportunities to study individual- and societal-level 
impact of bariatric surgery in a natural experiment, and could generate useful 
evidence to inform policy.
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8 CONCLUSIONS
• Registrations of bariatric surgery in the patient registry and the SOReg have 
a high level of accuracy, and these registries are appropriate data sources for 
studies on bariatric surgery. 
• Bariatric surgery seems to be associated with an overall decreased risk of 
cancer, with strongest impact on breast cancer, endometrial cancer and non-
Hodgkin lymphoma in women. However, the protective effect of bariatric 
surgery on cancer might decline with time after surgery. 
• Bariatric surgery might elevate the risk of colon cancer and kidney cancer, 
and colon cancer risk might increase further with time after surgery. 
• Bariatric surgery might be associated with increased disease-specific and 





Fetma är en av vår tids största folkhälsoproblem och ökar risken för flera allvarliga 
sjukdomar, inklusive diabetes och hjärt- och kärlsjukdomar. Flera studier har också 
påvisat en tydlig koppling mellan fetma och ökad cancerrisk. FN:s samarbets-
organisation för forskning om cancer (IARC) konkluderade att det finns gott veten-
skapligt underlag för att konstatera ett samband mellan fetma och ökad risk för cancer 
i bröst, livmoder, äggstockar, matstrupe, magsäck, bukspottkörtel, lever, gallblåsa, 
tjocktarm, ändtarm och benmärg. Det är dock oklart hur viktnedgång påverkar cancer-
risken. Det är dessutom okänt hur avsiktlig viktnedgång som inträffat innan cancer-
diagnos påverkar överlevnaden i cancersjukdom. Forskning i ämnet  försvåras av att 
konventionella behandlingsmetoder mot fetma sällan leder till uttalad och bestående 
viktnedgång. Fetmakirurgi är hittills den enda behandlingen med dokumenterade 
långtidseffekter på viktnedgång och fetmarelaterade sjukdomar. I denna avhandling 
har ingreppet därför använts för att studera effekten av viktnedgång på cancerrisk 
och canceröverlevand. 
Metoder och resultat
Studierna i avhandlingen bygger på en nordisk kohort (Nordic Obesity Surgery Cohort 
– NordOSCo) bestående av individer som fått diagnosen fetma registrerad i någon 
av de nationella patientregistren i Danmark, Finland, Island, Norge eller Sverige 
mellan åren 1980 och 2012. Kohorten innehåller även information från nationella 
cancerregister, dödsorsaksregister och befolkningsregister. 
I den första studien genomfördes en validering av fetmakirurgikoden i det svenska 
patientregistret och kvalitetsregistret för fetmakirurgi (Scandinavian Obesity Surgery 
Registry – SOReg). Ett slumpmässigt urval av registrerade fetmaoperation genom-
förda under 2011 i de båda registren jämfördes mot journaluppgifter. Resultaten 
påvisade god samstämmighet mellan journaluppgifterna och registren. I patient-
registret överens stämde 93.5% av de undersökta fetmaoperationerna, och motsva-
rande siffra för SOReg var 98.6%. En femtedel av operationerna i SOReg fanns dock 
inte i patient registret, vilket talar för inkomplett täckning av fetmaoperationer i detta 
register. Sammantaget tyder studien på att registren har god tillförlitlighet och kan 
användas för vetenskapliga studier om fetmakirurgi.
Den andra studien undersökte sambandet mellan fetmakirurgi och cancerrisk i 
NordOSCo. Separata analyser genomfördes för fetma-relaterad cancer, icke fetma-
relaterad cancer samt utvalda cancerlokalisationer. Fetmakirurgipatienter jämfördes 
mot patienter med fetmadiagnos som inte genomgått fetmakirurgi (kontrollgrupp), 
samt mot bakgrundsbefolkningen. Resultaten visade på lägre cancerinsjuknande efter 
fetmakirurgi vid jämförelse med kontrollgrupperna, i synnerhet för fetma-relaterad 
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cancer. Störst riskminskning noterades för bröst cancer, livmodercancer och non-
Hodgkin lymfom bland kvinnor. Sambanden var starkare tidigt efter fetmakirurgi, 
och avtog över tid efter operationen. Orsaken till den avtagande effekten är oklar, 
men kan delvis bero på att vikten hos många patienter successivt ökar igen efter 
den initiala drastiska viktnedgången. I studien noterades även en ökad risk för 
njurcancer efter fetmakirurgi, ett samband som behöver utredas i vidare studier. 
Den tredje och fjärde studien fokuserade på sambandet mellan fetmakirurgi 
och tjock- samt ändtarmscancer. I den tredje studien jämfördes risken för dessa 
cancrar bland fetmakirurgipatienter i NordOSCo mot samma kontrollgrupper 
som studie två. Resultaten visade på en 60% ökad risk för tjocktarmscancer bland 
fetmakirurgipatienter jämfört med bakgrundsbefolkningen. Motsvarande ökning 
bland patienter med fetmadiagnos och utan fetmakirurgi var 34%. Detta kan tyda 
på en ökad risk för tjocktarmscancer efter fetmakirurgi, även om det statistiska 
sambandet inte kunde säkerställas vid den direkta jämförelsen mellan fetma-
kirurgipatienter och kontrollgruppen med fetmadiagnos. Den ökade förekomsten 
av tjocktarmscancer var tydligast tio år eller längre efter kirurgi. Inget samband 
sågs mellan fetmakirurgi och ändtarmscancer. 
I den fjärde studien undersöktes sambandet mellan fetmakirurgi och överlevnad 
i tjocktarms- eller ändtarmscancer. I studien jämfördes fetmakirurgipatienter mot 
kontrollgruppen med fetmadiagnos och inkluderade endast svenska individer 
som insjuknat i en av dessa cancrar i NordOSCo. Inget samband sågs  mellan 
fetmakirurgi och överlevnad i tjocktarmscancer efter diagnos. Däremot var dödlig-
heten i ändtarmscancer trefaldigt ökad bland cancerpatienter med tidigare fetma-
kirurgi. Orsaken till den slående skillnaden i överlevnad mellan tjocktarms- och 
ändtarmscancer bland fetmakirurgipatienter är okänd. Denna studie lyfter för första 
gången frågan om fetmakirurgins inverkan på canceröverlevnad efter diagnos. 
Sammanfattning
Sammanfattningsvis så tyder studierna i denna avhandling på att uppgifter om 
fetmakirurgi från det svenska patientregistret lämpar sig för forskningsändamål. 
Den totala cancerrisken verkar minska efter fetmakirurgi. Betydelsen av opera-
tionen skiljer sig dock åt mellan olika tumörlokalisationer; störst riskminskning 
noterades för bröst- och livmodercancer medan en möjlig ökad risk kan föreligga 
för njur- och tjocktarmscancer. Med hänsyn till det sistnämnda fyndet samt  tidigare 
litteratur är det rimligt att fetmakirurgipatienter som söker med nytillkomna 
symptom från mag- och tarmkanalen utreds tidigt med koloskopi för att utesluta 
 tjocktarmscancer. Eventuellt kan utökad uppföljning i form av screening beaktas 
för fetmakirurgipatienter med ytterligare riskfaktorer för tjocktarmscancer. Den 
ökade dödligheten bland svenska patienter med ändtarmscancer efter fetmakirurgi 
bör efterföljas av mer forskning för att utreda eventuella samband mellan fetma-
kirurgi och cancer överlevnad i denna och övriga tumörlokalisationer.
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